What Researchers Study This Peptide For
Published research has examined this peptide in laboratory, animal and, where available, human studies involving the following areas:
Evidence represented: Laboratory • Mechanistic • Form-specific human evidence
- Growth-hormone release patternsMechanistic
- Pulsatile endocrine signalingMechanistic
- Growth-hormone-releasing hormone pathwaysLaboratory
- Pituitary signalingLaboratory
- IGF-1-related measurementsForm-specific human
- Peptide stability and receptor activityLaboratory
These topics describe areas of scientific investigation. Findings vary by study design, research model, formulation and evidence quality and should not be interpreted as established human outcomes.
What should you know first?
What Is CJC-1295 No DAC?
CJC-1295 no DAC refers to a GHRH-related research peptide lacking the albumin-binding Drug Affinity Complex used in long-acting CJC-1295.
GHRH means growth hormone–releasing hormone. Researchers examine signaling, degradation, stability, and measurements.
Ryse records verify the CJC-1295 (No DAC) name, a 10 mg vial listing, and a bundled COA titled for CJC no DAC 10 mg. They do not verify a sequence, formula, molecular weight, CAS number, or equivalence to modified GRF(1-29).
What Does “No DAC” Mean?
DAC stands for Drug Affinity Complex. The “no DAC” designation indicates that the albumin-binding modification associated with the longer-acting form of CJC-1295 is absent.
Published design papers describe CJC-1295 with DAC as a GHRH analog containing a reactive modification intended to bind albumin. That specifically identified DAC form was used in commonly cited limited human studies.
The no-DAC name distinguishes the listing from that form but does not establish a precise sequence or salt. Half-life comparisons are omitted because exact product identity was not verified.
CJC-1295 With DAC Versus No DAC
The key distinction is the presence or absence of the Drug Affinity Complex. Findings must be attributed to the molecular form actually studied.
With DAC
- Contains an albumin-binding modification
- Was designed for prolonged experimental activity
- Was used in commonly cited limited human studies
- Study findings apply only to the form identified in those publications
No DAC
- Does not contain that Drug Affinity Complex
- Commercial terminology may overlap with modified GRF(1-29)
- Exact sequence and identity should be verified from product-specific records
- DAC-study results should not automatically be transferred to no-DAC products
Is CJC-1295 No DAC the Same as Modified GRF(1-29)?
It should not be assumed. Some commercial sources use the names interchangeably, but naming practice is inconsistent and the current Ryse repository documentation does not verify that equivalence.
Compare sequence, form, expected and observed mass, and sample identifiers before treating two names as the same material.
GHRH-Related Biology
Growth hormone–releasing hormone is a signaling peptide involved in communication between the hypothalamus and pituitary gland. Researchers examine GHRH-related analogs to understand defined signaling and structural questions.
Experimental work may measure receptor activation, pituitary-cell responses, degradation, stability, analog design, or hormone patterns. These are research endpoints, not consumer benefits.
Molecular form remains central because modifications can change experimental behavior.
- GHRH receptor activity
- Pituitary signaling
- Peptide structure and stability
- Enzymatic degradation
- Structural analog design
- Hormone-measurement patterns
- Analytical detection and mass-spectrometric identification
- Differences between DAC and no-DAC forms
- Preclinical model development
What questions are researchers studying?
CJC-1295-related literature examines receptor biology, structural modification, analytical detection, and measurements made in preclinical or limited human research settings.
Check each paper's named compound, DAC status, model, controls, and endpoints. Commonly cited human publications concern the DAC form, not an unverified no-DAC product.
What are the limits of the current evidence?
Current evidence cannot establish human safety or effectiveness for the Ryse CJC-1295 no-DAC catalog material.
- Evidence depends on the exact peptide form studied.
- Most commercial products have not been evaluated in controlled human trials.
- DAC findings should not automatically be attributed to no-DAC material.
- Hormone measurements do not establish a clinical benefit.
- Short-term findings do not establish long-term safety.
- Research literature does not verify the identity or quality of a specific commercial batch.
- CJC-1295 is not FDA approved as a drug.
- Human safety and effectiveness have not been established.
Product Identity and COA Documentation
A CJC-1295 no-DAC COA should connect a defined sample to a product name, batch or lot, analytical methods, and reported results. Identity and purity are separate measurements.
Review available product and lot identifiers, sequence, expected and observed mass, purity, methods, chromatographic data, laboratory, dates, and limitations.
A COA does not prove sterility, safety, potency, stability, or suitability unless that attribute was appropriately tested and reported for the matched sample.
How should laboratories approach storage and handling?
Follow verified product-specific storage documentation and institutional laboratory procedures. The current article does not assign a storage temperature because product-specific stability support was not verified.
General laboratory guidance cannot replace product-specific stability data. This page intentionally provides no preparation, solvent, injection, route, timing, or personal-use instructions.
- Maintain the product and batch identification.
- Record storage conditions, duration, transfers, and excursions.
- Protect materials from inappropriate heat, moisture, or light where documented.
- Follow institutional handling and applicable laboratory disposal practices.
Frequently Asked Questions
What is CJC-1295 no DAC?
A commercial name for a GHRH-related research peptide without DAC. Confirm identity from product records.
What does no DAC mean?
The material is designated without the albumin-binding Drug Affinity Complex used in the DAC form.
Is CJC-1295 no DAC the same as CJC-1295 with DAC?
No. The DAC form contains a modification excluded by the no-DAC designation.
Is CJC-1295 no DAC the same as modified GRF(1-29)?
Do not assume so. Current Ryse records do not verify equivalence.
What does GHRH mean?
Growth hormone–releasing hormone, a signaling peptide involved in hypothalamus-to-pituitary communication.
Are there human studies involving CJC-1295?
Limited studies exist for the DAC form, not an unverified no-DAC material.
Is CJC-1295 FDA approved?
No. CJC-1295-related substances are not FDA approved as drugs, and FDA describes limited clinical data.
Is this product intended for human consumption?
No. Ryse products are for legitimate laboratory research only, not human or veterinary consumption.
What does a CJC-1295 COA show?
It reports identifiers, methods, dates, and results for a defined sample.
Does a COA prove a product is safe?
No. It documents reported tests, not general safety, approval, or untested qualities.
What is the difference between peptide identity and purity?
Identity evaluates compound consistency; purity estimates relative composition under a method.
Is this page medical advice?
No. It is research-literacy education and provides no medical or personal-use guidance.
Selected CJC-1295 no DAC Studies
External publications are provided for scientific-literacy purposes. Inclusion does not establish product equivalence, human safety, effectiveness, regulatory approval or suitability for personal use. Research involving CJC-1295 with DAC should not automatically be interpreted as research involving CJC-1295 no DAC.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
Describes the albumin-binding DAC form; it does not establish a no-DAC product's identity.
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone-releasing hormone, in healthy adults
A limited human study of the DAC form; its findings do not transfer to no-DAC material.
Advances in the detection of growth hormone releasing hormone synthetic analogs
Examines in-vitro metabolism and mass-spectrometric detection of several GHRH analogs.
Research Use Only
Information on this page is provided solely for general scientific education and laboratory-research literacy. It is not medical advice and does not provide dosing, reconstitution, administration or personal-use guidance.
Ryse Peptides products are intended only for legitimate laboratory research where legally permitted. They are not intended for human or veterinary consumption and are not intended to diagnose, treat, cure, mitigate or prevent any disease.
CJC-1295-related substances are not approved by the U.S. Food and Drug Administration as drugs. Published findings should not be interpreted as evidence of established human safety, effectiveness or clinical usefulness.